Category: Corona Virus

Page 297«..1020..296297298299..310320..»

COVID Symptoms vs. Cold: Here’s How to Spot the Difference – NBC Chicago

June 26, 2022

If you've come down with a runny nose or sore throat recently, you may be wondering whether it's the common cold, allergies or a COVID-19 infection.

Health officials say it can be difficult to tell what illness you're experiencing based on the symptoms, but getting tested is one way to find out -- including people who have been vaccinated, experts say.

"Even if it's a sore throat, no matter what it is," Dr. Allison Arwady, commissioner of the Chicago Department of Public Health, said in a Facebook live last month. "I've told my own staff this, it's what I do myself... if you are sick, even a little bit sick, stay home. More true than ever right now because sick, even a little bit sick, until proven otherwise with a test - that's COVID. That's how we treat it, that's how you should treat it."

According to the Centers for Disease Control and Prevention, the common cold, allergies and coronavirus overlap in some symptoms, like the potential for a cough, shortness of breath or breathing difficulties, fatigue, headaches, a sore throat and congestion.

Symptoms more associated with coronavirus include fever, muscle and body aches, loss of taste or smell, nausea or vomiting and diarrhea.

For some people, coronavirus causes mild or moderate symptoms that clear up in a couple weeks. For others, it may cause no symptoms at all. For some, the virus can cause more severe illness, including pneumonia and death.

Even those who receive the coronavirus vaccine can also still contract the virus and may experience symptoms.

Most vaccinated people either have no symptoms or exhibit very mild symptoms, according to health officials, and the virus rarely results in hospitalization or death for those individuals.

Coronavirus and the common cold share many symptoms.

According to the Mayo Clinic, diarrhea and nausea or vomiting are the only symptoms associated with coronavirus that don't overlap with the common cold.

The hospital also notes that whileCOVIDsymptoms generally appear two to 14 days after exposure to SARS-CoV-2, symptoms of a common cold usually appear one to three days after exposure to a cold-causing virus.

Dr. Katherine Poehling, an infectious disease specialist and member of the Advisory Committee on Immunization Practices,told NBC Newsin January that a cough, congestion, runny nose and fatigue appear to be prominent symptoms with the omicron variant.

However, unlike the delta variant, many patients are not losing their taste or smell. She noted that these symptoms may only reflect certain populations.

See the original post:

COVID Symptoms vs. Cold: Here's How to Spot the Difference - NBC Chicago

Britain is being hit by a new wave of Covid so what do we do now? – The Guardian

June 26, 2022

Britain is now going through its third major wave of Covid-19 infections this year. According to the ONS Infection Survey released last week, about 1.7 million people in the UK are estimated to have been infected in the week ending 18 June, a 23% rise on the previous week. This follows a 43% jump the previous week. The figures raise several important questions about how the nation will fare in the coming months as it struggles to contain the disease.

Most scientists and statisticians pin the latest jump on two fast-spreading Omicron sub-variants: BA.4 and BA.5. Crucially, two other countries Portugal and South Africa have experienced major jumps in numbers of cases due to these two sub-variants.

The waves in these countries have since peaked and neither resulted in a major increase in severe disease. Nevertheless, we should note there were some increases in hospitalisations, said John Edmunds, professor of infectious disease modelling at the London School of Hygiene and Tropical Medicine. The rise we are experiencing now is certainly not good news but it does not look, at present, like it has the potential to lead to disaster.

This point was backed by Stephen Griffin, associate professor at Leeds Universitys school of medicine We are in a better place now than in 2020 and 2021 due to the UK vaccine programme, he said. However, he warned the level of post-infections complications long Covid was troubling. It is abundantly clear the governments living with Covid strategy lacks long-term provision for wellbeing.

The government is already committed to vaccinating the over-65s, frontline health and social workers and vulnerable younger people in the autumn. However, the health and social care secretary Sajid Javid last week hinted that this might be extended to include all those over 50. The move would improve protection against Covid-19 at a time when immunity will have waned in much of the population.

However, the type of vaccine to be given is not yet settled with many scientists insisting it should be able to provide protection not just against the original Wuhan strain of Covid-19 but also against its most prevalent recent variant, Omicron. Moderna has developed such a vaccine, for example.

Omicron looks to be extremely fit, said James Naismith, of the Rosalind Franklin Institute in Oxford. We are now seeing different strains of it appearing, not a wholesale switch like the one we saw from Delta to Omicron. So I think it is perhaps unlikely we will see a completely new Omega strain, which makes it sensible to continue to target Omicron.

Sars-cov-2, the virus responsible for Covid-19, is not the first coronavirus that has been found to affect human beings. Other members of this class of virus cause mild respiratory illnesses and one day Covid-19 may reach a similar, relatively safe status in the population though not in the near future, says Prof Mark Woolhouse of Edinburgh University.

That situation will arise when the virus is circulating quite freely and people get infected multiple times as children, and so, by the time they get to be adults, they have actually built up pretty solid immunity - certainly against serious disease. However, its going to take a long time before we live in a population where most of us have had multiple exposures as children. That is decades away, though that does not mean we will be faced with severe public health problems for all that time. These problems will diminish - though there will be bumps on the way.

However, Woolhouse added, this is not going to settle down properly in my lifetime.

Read the original here:

Britain is being hit by a new wave of Covid so what do we do now? - The Guardian

Faster Progress Is Needed on Treatments for Long Covid – Bloomberg

June 26, 2022

Long Covid is making it hard for millions of Americans to return to normal life, pushing some out of the workforce altogether, sometimes permanently. Yet medical efforts to figure out how best to help these patients are proceeding only slowly.

Research has zeroed in on a few probable causes of long Covid, perhaps the most intriguing of which is the idea that the coronavirus sometimes lingers in the body undetected for months after an initial infection. The theories should not be difficult to investigate, and the National Institutes of Health has $1.2 billion to spend on the work. But its not moving fast enough.

See the original post:

Faster Progress Is Needed on Treatments for Long Covid - Bloomberg

Will COVID evolve to cause less severe disease? Why we can’t assume the answer is yes – San Francisco Chronicle

June 26, 2022

When scientists find a new disease-causing virus in humans, the first question they want answered is: Can this thing spread easily from person to person? And if not, will it someday?

Avian influenza can infect humans, but its not very good at passing from one person to another. Same with the coronavirus that causes MERS, another severe respiratory illness. Though hundreds of cases of both have been reported over the past two decades, neither virus seems inclined to evolve toward efficient person-to-person transmission.

In less than three years, the coronavirus that causes COVID-19 has mastered it.

SARS-CoV-2 has accumulated a suite of mutations over an astonishingly short period of time that have made it now one of the most infectious human pathogens on the planet. And for the first time ever, scientists have the tools and the knowledge to closely track that evolution in near-real time, studying the small but mighty genomic mutations that have transformed the virus to the point where it hardly resembles the strain that began infecting humans in China in late 2019.

Mapping the evolution of this virus has fed academically curious minds in every nation, and its had real world implications too. Identifying and describing new variants has helped guide public health responses and is now informing the next generation of vaccines and drug therapies.

The coronavirus rapid evolution also is helping scientists anticipate the future of the pandemic, and what mutations may make it a less or more formidable foe in years to come.

This is the first time in human history that weve been able to witness a global pandemic at the genomic, evolutionary level, said Joe DeRisi, president of San Franciscos Chan Zuckerberg Biohub, which has done genomic sequencing on the virus since the start of the pandemic.

Joe DeRisi, president of the Chan Zuckerberg Biohub, stands for a portrait on Thursday, Nov. 19, 2020, in San Francisco.

Whats been especially fascinating, and at times alarming, is the speed of this virus evolution. That SARS-CoV-2 would mutate to better adapt to humans was always anticipated, but the pace of that adaptation has been breathtaking.

Scientists say thats in large part due to the scale of the pandemic more than half a billion infections worldwide have afforded the virus near-boundless opportunity to mutate. But its a matter of timing, too. As a human virus, SARS-CoV-2 is still in its infancy, developing rapidly to flourish in its new environment. Meanwhile, human immunity to the virus due to infection and vaccination has become increasingly complex, applying constant pressure to further evolve.

Its normal to see this kind of evolution this constant battle between human and pathogen, said Fenyong Liu, an infectious disease expert at UC Berkeleys School of Public Health. Each of us is focused on survival. We develop a better system to beat them, and theyre going to mutate and try to escape. It happens with all infectious diseases, but for COVID, the whole process really sped up because of the scale of it.

Tanya Alexander waits in line for COVID-19 test with her grandson Sincere Perkins, 9, at Bayview Opera House in San Francisco on Thursday, Jan. 6, 2022.

Predicting how evolution will shape the next iterations of this virus is tricky, and scientists lack the technology to do it with any precision. How the virus has mutated over the past two and a half years provides some clues: Scientists have identified dozens of specific mutations mostly associated with increasing infectiousness that have recurred in multiple variants. Those mutations likely will keep showing up, re-sorting themselves in different combinations that give the virus further survival advantages. Some of the mutations could become permanently embedded in the virus genetic code. A few already have.

Recently, the virus has mutated to evade hard-won human immunity, and most experts in virology believe it will continue down that evolutionary path. It could also acquire new mutations that make it more infectious, though its already become so efficient at spreading among humans that its hard to imagine how much more gains it can make there, some scientists say.

The most critical question and possibly the toughest to answer is whether the virus will evolve to cause more or less severe disease in humans. Many experts believe that viruses tend to become more benign over time one of the current coronaviruses that now causes the common cold may have been the source of a deadly pandemic in the late 1800s but thats not a sure thing, and no one can say how long such evolution may take. Omicron and its subvariants are causing milder disease than their predecessors, but it would be nave to assume a future variant couldnt arrive with mutations that make it fiercer once again, experts say.

Social distancing circles at Dolores Park on Saturday, May 23, 2020, in San Francisco. The 10-foot circles, which were eight feet apart from each other, were an effort to curb coronavirus spread.

Hopefully it will adapt and become a very mild seasonal disease, and our immune systems will adapt, too, Liu said. But in reality, the virus has unlimited capability to adapt and mutate.

Scientists began tracking the evolution of SARS-CoV-2 almost immediately after the virus was isolated and identified in early January 2020. Once the first genomic sequence was complete and had been shared on a public database, infectious disease experts around the world started hunting for mutations, largely to keep tabs on how the virus was spreading.

Most people by now are familiar with the role mutations play in giving the virus certain advantages. But most mutations dont actually have an obvious effect on the virus, theyre simply glitches in the code. Those mutations can serve as evolutionary breadcrumbs, though, allowing scientists to follow the virus trail as it travels widely around the globe. And throughout the pandemic, public health experts have used mutations to identify and control clusters of infections.

Still, scientists are most invested in tracking consequential mutations that may alter the public health response. For example, arrival of the incredibly infectious omicron led many officials to recommend people start wearing higher quality masks, and eventually triggered another universal mask mandate in California to help curb the spread.

The most influential mutations mostly have been identified in the spike protein, the section of the virus that projects out of the surface and latches onto the ACE2 receptor, a protein on the exterior of human cells through which SARS-CoV-2 gains entry.

The first significant mutation known as D614G and nicknamed Doug arrived sometime in spring 2020; it basically made the ACE2 receptor more accessible. It was like putting a wedge in the door to keep it open, said Shannon Bennett, chief of science at the California Academy of Sciences.

Shannon Bennett, chief of science for the California Academy of Sciences, studies infectious diseases that can be transmitted from animals to humans. Here, she plays her piano at her home on March 20, 2020, in Mill Valley, Calif.

That mutation granted the virus an early boost in infectiousness, and it has stuck around in every important variant since. Identifying a mutation of that significance was surprising, and exciting, Bennett said. It was the kind of early evolutionary shift that scientists have never been able to capture before. With earlier viruses HIV, for example by the time scientists identified and were able to study them closely enough to look for mutations, they were already well established in humans and had likely gone through years of vigorous adaptations.

After D614G, the virus quickly accumulated mutations that mostly improved its ability to transmit and infect. Scientists havent yet determined exactly what all those changes are doing, at the biological level, to increase infectiousness. Some may allow the virus to replicate faster in the nose or bind more tightly to the ACE2 receptor, making it harder for the immune system to shake off an early infection. Mutations could also make the virus more durable, for instance able to survive for longer periods in the air.

By the end of 2020, it was becoming apparent that the virus was evolving quickly in an environment of widespread transmission. Troubling new variants were emerging at regular intervals, each causing new waves of infection in the country in which they emerged and sometimes on a global scale. And each new variant seemed to be at least somewhat more infectious than the one preceding it. Alpha, which dominated in the U.S. in early 2021, was perhaps 50% more infectious than the original virus, and delta, which fueled the summer 2021 surge, was perhaps 90% more infectious than alpha.

Nurse practitioner Paige Yang mixes a dose of Evusheld, a preventative monoclonal injection, at Total Infusion in Oakland, Calif. on March 16, 2022. The medication is used to prevent COVID-19 among immunocompromised patients.

Omicron, which carried dozens of new mutations, was again more infectious up to fivefold over delta. And each of its subvariants has been more infectious still. The currently circulating strains, all offspring of omicron, are nearly as infectious as measles, which is the most contagious of all known human infections.

Scientists say the virus may have hit peak infectiousness, or close to it. Now, its evolving to get around the immune response, and that trend likely will continue. Early studies show that the two up-and-coming variants in the U.S. BA.4 and BA.5, which currently make up roughly a third of cases are the most immune evasive so far; people who are vaccinated or have already been infected, or both, may still be vulnerable.

I think theres a max in terms of how transmissible it can be, said Nadia Roan, an investigator at the Gladstone Institutes in San Francisco who studies immunology. Now almost the entire world has some form of immunity, whether from infection or vaccination or both, and thats the big pressure. A virus that is able to take off right now has to be immune evasive.

Scientist Xiaoyu Luo, postdoctoral scholar Julie Frouard, lead scientist Nadia Roan, PhD, and research assistant Matthew McGregor wear masks and lab coats while walking through the lab at Gladstone Institutes in San Francisco on Thursday, August 13, 2020.

Immune evasion is such a concern that many experts believe the world needs to focus resources on developing next-generation vaccines that will target parts of the virus less prone to mutations. Manufacturers of the two main U.S. vaccines Pfizer and Moderna are working to update their products to better match the currently circulating variants, but thats difficult to do when the dominant variant changes every few months.

Ideally, scientists would develop a vaccine that neutralizes the virus preventing it from ever taking hold and stopping transmission entirely and doesnt fade over time. The latter may not be possible, though. It doesnt seem that this coronavirus will be inducing the same immunity that polio and measles induces that lasts for your entire life, said Raul Andino, a UCSF virologist.

Eventually, the pace of evolution in SARS-CoV-2 may slow down, or at least produce fewer consequential mutations that cause fresh surges several times a year. But its tough to guess when that will happen.

Virus evolution is relentless. The virus never takes a rest, never takes a break, and it never stops mutating, DeRisi said. The truce may come when we figure out what kind of yearly boosters we need, or what vaccination works.

We want to get the virus to where it just doesnt matter anymore, he said. Were not there yet. But theres reason to be optimistic, and also reason to be cautious and not let our guard down.

Erin Allday is a San Francisco Chronicle staff writer. Email: eallday@sfchronicle.com Twitter: @erinallday

Continue reading here:

Will COVID evolve to cause less severe disease? Why we can't assume the answer is yes - San Francisco Chronicle

Some long COVID patients still have virus in the blood; Paxlovid rebound patients may need longer treatment – Reuters

June 24, 2022

A healthcare worker collects a swab from a passenger for a PCR test against the coronavirus disease (COVID-19) before traveling to Uganda, amidst the spread of the new SARS-CoV-2 variant Omicron, at O.R. Tambo International Airport in Johannesburg, South Africa, November 28, 2021. REUTERS/ Sumaya Hisham/File Photo

Register

June 23 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Some long COVID patients still have virus in blood

Some cases of long COVID may be the immune system's response to a SARS-CoV-2 infection lurking somewhere in the body, new findings from a small study suggest.

Register

Researchers analyzed multiple plasma samples collected over time from 63 patients with COVID-19, including 37 who went on to develop long COVID. In the majority of those with long COVID, the spike protein from the surface of the virus was detectable for up to 12 months, whereas it was not present in plasma samples from recovered patients without lasting symptoms. Spike protein circulating in the blood could mean "a reservoir of active virus persists in the body," the researchers said in a paper posted on medRxiv last week ahead of peer review. Exactly where that reservoir might be is not clear from this study. Researchers said they have previously found active virus in the gastrointestinal tract of children weeks after the initial coronavirus infection, and other researchers have found genetic evidence of the virus "in multiple anatomic sites up to seven months after symptom onset."

If the results can be confirmed in larger studies, the presence of spike protein in the blood long after the initial infection may be one way to diagnose long COVID, the researchers said.

Paxlovid "rebound" patients may need longer treatment

The rebound of symptoms reported in some COVID-19 patients who took a five-day course of Pfizer's antiviral Paxlovid pills may be the result of insufficient treatment, according to researchers who closely evaluated one such patient.

Trial results showed that Paxlovid can reduce the risk of hospitalization and death from COVID-19 in high-risk patients by 89% if taken within five days of symptom onset. In some patients, however, virus levels and symptoms have rebounded after completing a course of Paxlovid, leading to concerns that variants might be developing resistance to the two-drug treatment or that the pills may somehow be weakening patients' antibody resistance. But when researchers isolated the Omicron BA.2 variant from a rebound patient and tested it in lab experiments, they found it was still sensitive to Paxlovid and had no mutations that would reduce the drug's effectiveness. They also found their patient's antibodies could still block the virus from entering and infecting new cells.

The rebound of COVID-19 symptoms after Paxlovid treatment is likely happening because not enough of the drug is reaching infected cells to completely stop the virus from making copies of itself, the researchers said in a paper published on Monday in Clinical Infectious Diseases. It is also possible that the drug may be metabolized, or processed, at different rates in different people, or that some people need to take it for more than five days.

After COVID-19, kids have more symptoms but less anxiety

Persistent health problems were only slightly more common in children after COVID-19 than in similarly-aged kids who avoided the virus, researchers from Denmark reported on Wednesday in The Lancet Child & Adolescent Health. Anxiety levels, however, were higher in children who never had COVID-19, the researchers also found.

They said 40% of infants and toddlers with COVID-19 and 27% of their uninfected peers experienced at least one symptom for more than two months. Among kids ages 4 to 11, persistent symptoms were seen in 38% with COVID-19 and 34% without it. And among 12- to 14-year-olds, 46% of those with COVID-19 and 41% of those without it had long-lasting symptoms. The results were based on a survey of nearly 11,000 mothers of infected children and nearly 33,000 mothers of uninfected kids.

While symptoms associated with long COVID such as headache, mood swings, abdominal pain and fatigue are often experienced by otherwise healthy children, infected children had longer-lasting symptoms and one-third had new symptoms that developed after COVID-19. To the researchers' surprise, children who had COVID-19 experienced fewer psychological and social problems than those in the control group. They speculated this may be because the uninfected children had more "fear of the unknown disease and more restricted everyday life due to protecting themselves from catching the virus."

Click for a Reuters graphic on vaccines in development.

Register

Reporting by Nancy Lapid; Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Follow this link:

Some long COVID patients still have virus in the blood; Paxlovid rebound patients may need longer treatment - Reuters

Study analyzing the link between peoples movement and coronavirus spread finds three groups of countries – News-Medical.Net

June 24, 2022

A new study analyzing the link between people's reduced movement and the spread of coronavirus in 2020 shows that in some countries, the virus spread more rapidly when people stayed at home. In addition, restricting people's mobility to some extent appeared, retrospectively, to be better at minimizing the spread of SARS-CoV-2 than extreme mobility restrictions, in many countries.

"Over two years mark the start of the pandemic which changed the lives of many of us in various ways. The current development of the SARS-CoV-2 spread suggests that this chapter of history entitled COVID-19 might, hopefully, be fading to its end. There is, however, still a lot to learn about it. Reflecting on how we have reacted to the pandemic could help us draw useful lessons on how to minimize the damage of similar challenges, especially now that infectious diseases appear to be a re-emerging threat," researchers Mounir Ould Setti and Sylvain Tollis point out.

Government-imposed lockdowns and movement restrictions were likely the hallmark of the response to this pandemic. These interventions were found invasive in some circumstances and settings. Were lockdowns and movement restrictions efficient in reducing SARS-CoV-2 spread? The researchers from the University of Eastern Finland analyzed how the movement of people aligned with daily changes of the effective replication number of SARS-CoV-2. The effective replication number reflects the rate of spread of the disease as it captures dynamic changes in person-to-person viral transmission. The mobility indicators are based on anonymized position data from users of Google services who have Location History activated on their mobile phones. The positions are classified into different mobility categories, including, for example, residential mobility, which indicates that people are staying at home. The researchers focused on the pre-vaccination and pre-variants-of-concern phase of the pandemic from February 15 to December 31, 2020 analyzing daily changes of mobility and SARS-CoV-2 spread in 125 countries and 52 United States regions or states.

The analysis identified three groups of countries based on patterns of correlations between the mobility indicators and the effective reproduction number of SARS-CoV-2. Group 1 consisted of countries with "normal" correlations, in other words negative correlations between residential mobility and SARS-CoV-2 spread, e.g. the United States, Turkey, and most OECD countries. Group 2 included countries with "inverted" correlations, referring to positive correlations between residential mobility and SARS-CoV-2 spread. Group 3 consisted of countries with more complex correlation patterns, or "inconclusive" correlations.

In group 1 countries such as Austria, the more time people spent at home, the less disease spread was recorded, while in group 2 countries such as Bolivia, the exact opposite was observed: the more time people spent at home, the more disease was spreading. In addition, in many countries, the patterns of correlation between mobility and disease spread displayed a minimum of disease spread at an intermediate level of mobility restriction ("U-shaped" correlations), indicating an optimal level above which restricting people's mobility could lead to more disease spread. In other words, complete lockdowns might have been counterproductive at certain levels and in some countries.

The authors concluded that a systematic analysis of correlations between mobility and disease spread at a regional level could help understand the optimal level of mobility restriction that minimizes the spread of SARS-CoV-2 in that specific region.

Source:

Journal reference:

In-depth Correlation Analysis of SARS-CoV-2 Effective Reproduction Number and Mobility Patterns: Three Groups of Countries. J Prev Med Public Health.Published online 10 Feb 2022.doi.org/10.3961/jpmph.21.522

More:

Study analyzing the link between peoples movement and coronavirus spread finds three groups of countries - News-Medical.Net

20 million lives saved by COVID-19 vaccines in first year: report – New York Post

June 24, 2022

The coronavirus pandemic could have been much worse without vaccines, according to a new study that claims the number of deaths recorded worldwide from the coronavirus would be more than triple than it is today.

In the year after the vaccine was first introduced in December 2020, more than 4.3 billion people received an inoculation, saving 20 million lives, according to research published Thursday in the journal Lancet Infectious Diseases.

If the World Health Organizations goal of 40% vaccination coverage by the end of 2021 in low-income countries had been met, an additional 600,000 lives would be spared, the study said.

The findings quantify just how much worse the pandemic could have been if we did not have these vaccines, said lead Imperial College London researcher Oliver Watson.

Catastrophic would be the first word that comes to mind, Watson said of the deaths that would have occurred without widespread vaccination.

More than 6.3 million people have died from the coronavirus, including more than a million Americans, according to Our World in Data. Over 40,000 New York City residents died from the virus, health officials said.

Researchers studied data from all but ten of the worlds 195 countries and found that vaccines prevented 19.8 million total deaths, including 4.2 million deaths in India and 1.9 million in the US.

One million people in Brazil were also spared death from the virus thanks to the vaccines, as were more than a half million people in both France and the United Kingdom, researchers said.

The study found that 14.4 million deaths were averted when only accounting for reported COVID-19 deaths, but the number of lives spared grew considerably when scientists accounted for deaths likely tied to the virus.

The study did have some significant limitations. China, the worlds most populated country, was among the countries excluded from the study due to the lack of information about the virus effect on its huge citizenry, researchers said. The effect of mask wearing, lockdowns and possible COVID-19 mutations in the absence of the virus were also not considered in the study.

An unpublished model by the Institute for Health Metrics and Evaluation in Seattle estimated that 16.3 million lives were saved by vaccines.

We may disagree on the number as scientists, but we all agree that COVID vaccines saved lots of lives, the institutes Ali Mokdad said, explaining that stricter policies would have been implemented worldwide if vaccines were not around during the delta variant surge.

Although we did pretty well this time we saved millions and millions of lives we could have done better and we should do better in the future, said Adam Finn of Bristol Medical School in England, who was not involved in Thursdays published findings.

With AP wires

See the rest here:

20 million lives saved by COVID-19 vaccines in first year: report - New York Post

Dutch Research On Long Covid Shows 50% Of Study Participants Have 1 Or More Symptoms 3 Months After Becoming Infected With Coronavirus – Forbes

June 24, 2022

THE HAGUE, NETHERLANDS: Director of the Dutch RIVM (Center for Infectious Disease Control) Jaap van ... [+] Dissel. (Photo by Niels Wenstedt/BSR Agency/Getty Images)

The Dutch RIVM (Center for Infectious Disease Control - CDC counterpart in the Netherlands) is conducting a long-term study on long Covid. The agency released interim results on Tuesday, June 21st, which show that approximately 50% of patients enrolled in a large ongoing study still have one or more symptoms three months after becoming infected with the coronavirus SARS-CoV-2. In addition, among adults under the age of 65, researchers detected no difference between those who are vaccinated and unvaccinated in terms of most long Covid symptoms, except for sense of smell and taste. Vaccinated adults reported less loss of smell and taste than than those who were unvaccinated.

Long Covid is a hotly debated subject. In particular, some experts have worried about lack of clarity around long Covids characterization, and causal inferences which arent necessarily well established. And so, the key questions become, what exactly are long Covid symptoms, and how likely is it that a coronavirus infection caused them?

There isnt a firm consensus on long Covids precise definition, and causality is still being analyzed by clinical researchers. Yet, since fairly early in the pandemic, a broad set of symptoms we now refer to as long Covid the literature used to label sufferers as long-haulers has been very well documented. The Dutch RIVM, in particular, has meticulously collected data on long Covid, both to characterize the syndrome and attempt to figure out whats causing symptoms.

Its evident that many people who contract the coronavirus struggle for months with lingering Covid-19 symptoms which can be debilitating. Patients exhibit shortness of breath, extreme fatigue, intermittent fevers, cough, concentration issues, chest pressure, headaches, and heart palpitations, among other symptoms.

There is a very wide range in estimates of long Covid prevalence among those who recover from a symptomatic coronavirus infection. A University of California Davis study found that 10% of Covid-19 patients suffer from long Covid symptoms. In a CDC-sponsored study, it was estimated that around 20% of adults under 65 who recover from Covid-19 experience at least one health condition that could be considered long Covid. Here, CDC researchers identified persistent health problems in different organs of the body, including the heart, lungs, and kidneys. Yet another study suggested that 30% develop at least one long Covid symptom over time.

Fatigue, shortness of breath, brain fog, and loss of smell are particularly common long-term effects of Covid-19. This is apparent from the studies mentioned above, but also the interim results of the RIVM's study released on June 21st. For some, symptoms are relatively minor. For others, however, they can be disabling and life-altering.

The preliminary findings from the RIVM investigation refer to data gathered from May to December 2021. As such, they concern people who became infected with the Alpha or Delta variants of the coronavirus.

The results derive from a health survey questionnaire taken by a total of 14,572 participants. 9,166 people took the survey shortly after testing positive for SARS-CoV-2. The control group consisted of 5,406 people who tested negative for the coronavirus and applied to take part in the survey or were invited by letter from the general population. RIVM requested that all survey participants fill out questionnaires about their health at intervals of three months.

Around 33% of study participants who became infected with coronavirus still suffer from fatigue three months later. Persistent shortness of breath occurs in 16% of respondents, 15% have ongoing brain fog, and 12% have chronic loss of their normal sense of smell and taste for at least three months after their initial infection.

Whats striking is that these reported symptoms are 1.5 times more common among Covid-19 patients than among those who have had other (non Covid-19) respiratory infections.

The Dutch research also demonstrates that fully vaccinated people under 65 years of age who contracted coronavirus have fewer problems with smell and taste after three months. For other symptoms, however, no difference was found between vaccinated and unvaccinated people.

The RIVM will continue to follow up with study participants for at least one year. And, the agency will eventually include results from those who became infected with the Omicron variant.

The Dutch investigation not only shows that a large percentage of Covid-19 patients continue to have symptoms after recovery from the acute, initial coronavirus infection, but also suggests that the constellation of long Covid symptoms is much more common in these patients than in people in the general population, and in patients who experienced other (non Covid-19) respiratory infections.

While there continue to challenges regarding how to precisely define long Covid and how to determine cause and effect, ignoring or downplaying the long Covid syndrome isnt going to make it go away. Its vital that more research is carried out to determine causality and to find therapies that work for long-haulers.

View post:

Dutch Research On Long Covid Shows 50% Of Study Participants Have 1 Or More Symptoms 3 Months After Becoming Infected With Coronavirus - Forbes

Coronavirus Omicron variant, vaccine, and case numbers in the United States: June 23, 2022 – Medical Economics

June 24, 2022

Patient deaths: 1,014,835

Total vaccine doses distributed: 758,129,055

Patients whove received the first dose: 259,198,178

Patients whove received the second dose: 221,924,152

% of population fully vaccinated (both doses, not including boosters): 66.8%

% tied to Omicron variant: 100%

% tied to Other: 0%

Continued here:

Coronavirus Omicron variant, vaccine, and case numbers in the United States: June 23, 2022 - Medical Economics

Page 297«..1020..296297298299..310320..»